Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN (AMGN)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 08/16 10:00:02 pm
196.44 USD   +0.60%
08/16AMGEN : Ex-dividend day for
FA
08/14BIOCENTURY - MA : FDA, Allergan
AQ
08/03AMGEN : Breaks Ground On Next-Generation Biomanufacturing Plant in R..
AQ
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/10/2018 08/13/2018 08/14/2018 08/15/2018 08/16/2018 Date
194.42(c) 195.61(c) 195.76(c) 195.26(c) 196.44(c) Last
1 769 156 1 802 944 1 240 203 1 900 152 2 361 748 Volume
+0.23% +0.61% +0.08% -0.26% +0.60% Change
More quotes
Financials (USD)
Sales 2018 23 119 M
EBIT 2018 11 577 M
Net income 2018 8 745 M
Finance 2018 3 583 M
Yield 2018 2,65%
Sales 2019 22 805 M
EBIT 2019 11 516 M
Net income 2019 8 757 M
Finance 2019 7 861 M
Yield 2019 2,82%
P/E ratio 2018 15,30
P/E ratio 2019 14,78
EV / Sales2018 5,31x
EV / Sales2019 5,20x
Capitalization 126 B
More Financials
Company
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics.Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha,... 
Sector
Pharmaceuticals
Calendar
08/16Ex-dividend day for
More about the company
Surperformance© ratings of Amgen
Trading Rating : Investor Rating :
More Ratings
Latest news on AMGEN
08/16AMGEN : Reports from Amgen Describe Recent Advances in Monoclonal Antibodies (Sc..
AQ
08/16AMGEN : Ex-dividend day for
FA
08/14BIOCENTURY - MANAGEMENT TRACKS : FDA, Allergan
AQ
08/09AMGEN : Patent Issued for Method For Treating Melanoma Using A Herpes Simplex Vi..
AQ
08/09AMGEN : Reports from Amgen Advance Knowledge in Rheumatoid Arthritis (Two-Year A..
AQ
08/09AMGEN : Breaks Ground On Next-Generation Biomanufacturing Plant In Rhode Island
AQ
08/04AMGEN : Breaks Ground On Next-Generation Biomanufacturing Plant In Rhode Island
AQ
08/03AMGEN : Breaks Ground On Next-Generation Biomanufacturing Plant in Rhode Island
AQ
08/03AMGEN : Announces 2018 Third Quarter Dividend
AQ
08/02AMGEN : New Biopharmaceuticals Study Findings Recently Were Reported by Research..
AQ
More news
Sector news : Pharmaceuticals - NEC
08:15aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
08/16TEVA PHARMACEUTICAL INDUSTRIES : Antares Pharma Shares Rise After FDA Approves F..
DJ
08/16GLAXOSMITHKLINE : to Close Skincare Factory in Ireland
DJ
08/16BASF : Bayer says can begin integration of Monsanto
RE
08/16REGENERON PHARMACEUTICALS : Teva Report Positive Phase 3 Fasinumab Results
DJ
More sector news : Pharmaceuticals - NEC
MarketScreener Strategies on AMGEN 
AMGEN - 03/05
The technical configuration is positive
BUY
AMGEN - 2017
Back on key levels based on weekly price data
BUY
More Strategies
Latest Tweets
08/16Osiris Therapeutics $OSIR vs. Amgen $AMGN Head-To-Head Contrast  
08/15Amgen Inc (NASDAQ:AMGN): What You Have To Know Before Buying For The Upcoming.. 
08/15$AMGN ALERT: New Amgen SEC Filing From our Stock News Alerts App 
08/14. and senior portfolio analyst break down why Amgen $AMGN was the right pill.. 
08/14Amgen: Cramer and Marks Discuss the AAP Portfolio's New Edition  
More tweets
Qtime:217
News from SeekingAlpha
08/15Investors shun healthcare stocks in broad market selloff 
08/09ROCHE : Details On Growing Through The Patent Cliff (Part 2 Of 2) 
08/09BeiGene launches late-stage study of tislelizumab in first-line lung cancer 
08/07AbbVie Is Looking For New Growth Before Generic Competitors Roll In 
08/07BIOPHARMA 2018 : Growth At A Reasonable Cost (GARC) 
Chart AMGEN
Duration : Period :
Amgen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 204 $
Spread / Average Target 4,0%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline CFO, Chief Accounting Officer & Executive VP
David M. Reese Executive Vice President-Research & Development
Frank C. Herringer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN12.28%126 710
JOHNSON & JOHNSON-5.18%347 417
PFIZER14.36%238 136
NOVARTIS-0.83%207 488
ROCHE HOLDING LTD.-2.96%206 696
MERCK AND COMPANY22.36%176 752